Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activity is a research paper published in JCI Insight (2024). On theSindex it has a DataRank of 0. It has been cited 10 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH
Grant: R01 AI157155,HHSN272201400008C,75N93021C00014,75N93019C00051,HHSN272201700060C,75N93019C00062
NIAID NIH HHS
Grant: HHSN272201400008C
NCATS NIH HHS
Grant: UL1 TR002345
NIAID NIH HHS
Grant: HHSN272201700060C
NIAID NIH HHS
Grant: 75N93019C00051
NIGMS NIH HHS
Grant: T32 GM007200
NIAID NIH HHS
Grant: 75N93019C00062
NIAID NIH HHS
Grant: T32 AI007172
NIAID NIH HHS
Grant: 75N93021C00014
NIAID NIH HHS
Grant: R01 AI157155
National Institutes of Health
Grant: 5R01AI157155-02
Human antibody-based countermeasures against the Coronavirus SARS-CoV-2
National Institutes of Health
Grant: 1UL1TR002345-01
Washington University Institute of Clinical and Translational Sciences
National Institutes of Health
Grant: 5T32AI007172-37
Infectious Disease/Basic Microbial Pathogenic Mechanisms
FWCI
3.53
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals